p16_37-63 peptide without montanide® isa-51 vg
HPV-induced Cancers
Oryx GmbH & Co. KGprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HPV-induced Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Montanide Isa 51 Oryx GmbH & Co. KG | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →